SIOX   $0.41  -1.01% Market Closed

Last Events:

2023-03-29 Trend pattern changed from канал to восходящий клин.

2023-03-29 Signal in Stochastic changed from bearish recovery to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: signal line crossed the middle level.

2023-03-29 Signal in MACD changed from bearish recovery to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-03-29 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA50 changed from bearish reversal to bullish reversal. 2023-02-10 the price crossed up the moving average line and formed a short-term upside trend.

2023-03-29 Trend Power changed from slow to medium strength.

2023-03-29 Trend changed from up and flat to flat and up.

2023-03-29 Trend pattern changed from восходящий клин to канал.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 5.00
Mean unverified/preliminary 5.00 / 5.00
Target Price Low / High 5.00 / 5.00
Median / STD DEV 5.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy -
rsi ActivelyBuy ActivelyBuy -
macd - - -
stoch - - -
ma20 - - -
ma50 - - -
ma100 ActivelyBuy ActivelyBuy -
Candlestick PatternMarch 2, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US8293991043
ceo Mr. David W. Nassif J.D.
Website https://www.siogtx.com
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.